These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 1851660)
1. Antitumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice. Siegall CB; Kreitman RJ; FitzGerald DJ; Pastan I Cancer Res; 1991 Jun; 51(11):2831-6. PubMed ID: 1851660 [TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40). Pai LH; Gallo MG; FitzGerald DJ; Pastan I Cancer Res; 1991 Jun; 51(11):2808-12. PubMed ID: 2032221 [TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein. Arteaga CL; Hurd SD; Dugger TC; Winnier AR; Robertson JB Cancer Res; 1994 Sep; 54(17):4703-9. PubMed ID: 8062268 [TBL] [Abstract][Full Text] [Related]
4. [Specific cytotoxicity of recombinant interleukin 6-pseudomonas exotoxin fusion protein (IL6-PE40) on LT12 leukemic cells expressing high levels of interleukin 6 receptor (IL6R)]. Xi YZ Zhonghua Zhong Liu Za Zhi; 1993 Nov; 15(6):419-22. PubMed ID: 8200278 [TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of IL6-PE40 and derivatives on tumor cells expressing a range of interleukin 6 receptor levels. Siegall CB; FitzGerald DJ; Pastan I J Biol Chem; 1990 Sep; 265(27):16318-23. PubMed ID: 2118904 [TBL] [Abstract][Full Text] [Related]
6. Cell-specific toxicity of a chimeric protein composed of interleukin-6 and Pseudomonas exotoxin (IL6-PE40) on tumor cells. Siegall CB; Nordan RP; FitzGerald DJ; Pastan I Mol Cell Biol; 1990 Jun; 10(6):2443-7. PubMed ID: 2160579 [TBL] [Abstract][Full Text] [Related]
7. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo. Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895 [TBL] [Abstract][Full Text] [Related]
8. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin. Kioi M; Kawakami K; Puri RK Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012 [TBL] [Abstract][Full Text] [Related]
9. Expression of high-affinity interleukin 4 receptors on murine sarcoma cells and receptor-mediated cytotoxicity of tumor cells to chimeric protein between interleukin 4 and Pseudomonas exotoxin. Puri RK; Ogata M; Leland P; Feldman GM; FitzGerald D; Pastan I Cancer Res; 1991 Jun; 51(11):3011-7. PubMed ID: 2032239 [TBL] [Abstract][Full Text] [Related]
10. Small chimeric toxins containing only transforming growth factor alpha and domain III of Pseudomonas exotoxin with good antitumor activity in mice. Kihara A; Pastan I Cancer Res; 1994 Oct; 54(19):5154-9. PubMed ID: 7923133 [TBL] [Abstract][Full Text] [Related]
11. [Molecular design and construction of IL6D24-PE40KDEL, a novel recombinant interleukin6-pseudomonas exotoxin fusion protein, having targeted cytotoxicity for leukemias expressing interleukin6 receptors]. Zheng LY; Xi YZ; Kong FH; Cui JW; Liang F; Liu N; Sun YY; Guo SQ Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(14):1246-50. PubMed ID: 12930640 [TBL] [Abstract][Full Text] [Related]
12. Targeting interleukin-4 receptors for effective pancreatic cancer therapy. Kawakami K; Kawakami M; Husain SR; Puri RK Cancer Res; 2002 Jul; 62(13):3575-80. PubMed ID: 12097255 [TBL] [Abstract][Full Text] [Related]
13. Abrogation of head and neck squamous cell carcinoma growth by epidermal growth factor receptor ligand fused to pseudomonas exotoxin transforming growth factor alpha-PE38. Thomas SM; Zeng Q; Epperly MW; Gooding WE; Pastan I; Wang QC; Greenberger J; Grandis JR Clin Cancer Res; 2004 Oct; 10(20):7079-87. PubMed ID: 15501988 [TBL] [Abstract][Full Text] [Related]
14. Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy. Kioi M; Takahashi S; Kawakami M; Kawakami K; Kreitman RJ; Puri RK Cancer Res; 2005 Sep; 65(18):8388-96. PubMed ID: 16166317 [TBL] [Abstract][Full Text] [Related]
15. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy. Kawakami M; Kawakami K; Stepensky VA; Maki RA; Robin H; Muller W; Husain SR; Puri RK Clin Cancer Res; 2002 Nov; 8(11):3503-11. PubMed ID: 12429641 [TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo. Hitomi M; Yokoyama F; Kita Y; Nonomura T; Masaki T; Yoshiji H; Inoue H; Kinekawa F; Kurokohchi K; Uchida N; Watanabe S; Kuriyama S Int J Oncol; 2005 Mar; 26(3):713-20. PubMed ID: 15703828 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms of dichotomous action of IL-2-Pseudomonas exotoxin 40 (IL-2-PE40) on cell-mediated and humoral immune response. Volk HD; Müller S; Yarkoni S; Diamantstein T; Lorberboum-Galski H J Immunol; 1994 Sep; 153(6):2497-505. PubMed ID: 8077661 [TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells. Kunwar S; Pai LH; Pastan I J Neurosurg; 1993 Oct; 79(4):569-76. PubMed ID: 7692018 [TBL] [Abstract][Full Text] [Related]
19. Selective killing of IL6 receptor bearing myeloma cells using recombinant IL6-Pseudomonas toxin. Siegall CB; FitzGerald DJ; Pastan I Curr Top Microbiol Immunol; 1990; 166():63-9. PubMed ID: 2127396 [No Abstract] [Full Text] [Related]
20. IL2-PE664Glu, a new chimeric protein cytotoxic to human-activated T lymphocytes. Lorberboum-Galski H; Garsia RJ; Gately M; Brown PS; Clark RE; Waldmann TA; Chaudhary VK; FitzGerald DJ; Pastan I J Biol Chem; 1990 Sep; 265(27):16311-7. PubMed ID: 1975810 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]